Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease

Kidney International

Volumn 85, Issue 1, 2014, Pages 103-111

  Posada Ayala, Maria ^a   Zubiri, Irene ^a   Martin Lorenzo, Marta ^a   Sanz Maroto, Aroa ^a   Molero, Dolores ^b   Gonzalez Calero, Laura ^a   Fernandez Fernandez, Beatriz ^a   De La Cuesta, Fernando ^c   Laborde, Carlos M ^c   Barderas, Maria G ^c   Ortiz, Alberto ^a   Vivanco, Fernando ^a,b   Alvarez Llamas, Gloria ^a  

^a UAM)   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

chronic kidney disease; mass spectrometry; metabolomics; nuclear magnetic resonance; selected reaction monitoring; urine

Indexed keywords

ACETIC ACID DERIVATIVE; ALPHA PHENYLACETYLGLUTAMINE; AMINO ACID; CITRIC ACID; GLUTAMIC ACID; GUANIDOACETATE; PYROGLUTAMIC ACID; TAURINE; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEMICAL ANALYSIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; PRIORITY JOURNAL; SELECTED REACTION MONITORING; TRIPLE QUADRUPOLE MASS SPECTROMETRY; URINALYSIS; VALIDATION PROCESS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MASS SPECTROMETRY; METABOLOME; MIDDLE AGED;

EID: 84891556715     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.328     Document Type: Article

References (22)

1. Peralta CA, Shlipak MG, Judd S et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-To-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305: 1545-1552.
2. Messerli FH. The sudden demise of dual renin-Angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009; 53: 468-470.
3. Fassett RG, Venuthurupalli SK, Gobe GC et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-821.
4. Smith MP, Banks RE, Wood SL et al. Application of proteomic analysis to the study of renal diseases. Nat Rev Nephrol 2009; 5: 701-712.
5. Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol 2012; 8: 22-33.
6. Shah VO, Townsend RR, Feldman HI et al. Plasma metabolomic profiles in different stages of CKD. Clin J Am Soc Nephrol 2013; 8: 363-370.
7. van der Kloet FM, Tempels FW, Ismail N et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 2012; 8: 109-119.
8. Diercks DB, Owen K, Tolstikov V et al. Urinary metabolomic analysis for the identification of renal injury in patients with acute heart failure. Acad Emerg Med 2012; 19: 18-23.
9. Lange V, Picotti P, Domon B et al. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008; 4: 222.
10. Picotti P, Bodenmiller B, Aebersold R. Proteomics meets the scientific method. Nat Methods 2013; 10: 24-27.
11. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009; 30: 42-59.
12. Stumvoll M, Perriello G, Meyer C et al. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int 1999; 55: 778-792. (Pubitemid 29100691)
13. Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 1991; 29: 147-150.
14. Zimmerman L, Egestad B, Jornvall H et al. Identification and determination of phenylacetylglutamine, a major nitrogenous metabolite in plasma of uremic patients. Clin Nephrol 1989; 32: 124-128. (Pubitemid 19228225)
15. Suliman ME, Barany P, Filho JC et al. Accumulation of taurine in patients with renal failure. Nephrol Dial Transplant 2002; 17: 528-529.
16. Bergstrom J, Alvestrand A, Furst P et al. Sulphur amino acids in plasma and muscle in patients with chronic renal failure: evidence for taurine depletion. J Intern Med 1989; 226: 189-194. (Pubitemid 19226069)
17. Bain MA, Faull R, Fornasini G et al. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant 2006; 21: 1300-1304.
18. Bell JD, Lee JA, Lee HA et al. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. Biochim Biophys Acta 1991; 1096: 101-107.
19. Phisitkul S, Khanna A, Simoni J et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010; 77: 617-623.
20. Gao X, Chen W, Li R et al. Systematic variations associated with renal disease uncovered by parallel metabolomics of urine and serum. BMC Syst Biol 2012; 6(Suppl 1): S14.
21. Qi S, Ouyang X, Wang L et al. A pilot metabolic profiling study in serum of patients with chronic kidney disease based on (1) H-NMR-spectroscopy. Clin Transl Sci 2012; 5: 379-385.
22. Lauridsen M, Hansen SH, Jaroszewski JW et al. Human urine as test material in 1H NMR-based metabonomics: recommendations for sample preparation and storage. Anal Chem 2007; 79: 1181-1186.